TT International Has $989,000 Position in Bristol-Myers Squibb Co (NYSE:BMY)

TT International cut its position in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 43.5% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,518 shares of the biopharmaceutical company’s stock after selling 11,953 shares during the period. TT International’s holdings in Bristol-Myers Squibb were worth $989,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of BMY. Sterling Capital Management LLC grew its holdings in shares of Bristol-Myers Squibb by 2.6% during the 3rd quarter. Sterling Capital Management LLC now owns 980,911 shares of the biopharmaceutical company’s stock worth $62,523,000 after purchasing an additional 24,629 shares in the last quarter. Coldstream Capital Management Inc. boosted its stake in Bristol-Myers Squibb by 8.4% in the 3rd quarter. Coldstream Capital Management Inc. now owns 13,717 shares of the biopharmaceutical company’s stock valued at $874,000 after buying an additional 1,062 shares in the last quarter. Northern Oak Wealth Management Inc. boosted its stake in Bristol-Myers Squibb by 0.7% in the 3rd quarter. Northern Oak Wealth Management Inc. now owns 138,733 shares of the biopharmaceutical company’s stock valued at $8,843,000 after buying an additional 968 shares in the last quarter. Green Square Capital LLC boosted its stake in Bristol-Myers Squibb by 52.2% in the 3rd quarter. Green Square Capital LLC now owns 5,828 shares of the biopharmaceutical company’s stock valued at $371,000 after buying an additional 2,000 shares in the last quarter. Finally, Griffin Asset Management Inc. boosted its stake in Bristol-Myers Squibb by 3.7% in the 3rd quarter. Griffin Asset Management Inc. now owns 176,923 shares of the biopharmaceutical company’s stock valued at $11,277,000 after buying an additional 6,354 shares in the last quarter. 69.56% of the stock is currently owned by institutional investors and hedge funds.

BMY has been the subject of several research analyst reports. Citigroup set a $72.00 price objective on Bristol-Myers Squibb and gave the company a “buy” rating in a research report on Wednesday, October 25th. Vetr downgraded Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $59.70 price objective for the company. in a research report on Friday, December 22nd. BMO Capital Markets set a $49.00 target price on Bristol-Myers Squibb and gave the stock a “sell” rating in a research report on Thursday, October 26th. Zacks Investment Research downgraded Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a research report on Monday, January 29th. Finally, Credit Suisse Group set a $62.00 price objective on Bristol-Myers Squibb and gave the stock a “hold” rating in a research note on Monday, January 22nd. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $66.36.

Shares of Bristol-Myers Squibb Co (NYSE BMY) traded up $3.57 during midday trading on Thursday, hitting $68.92. The stock had a trading volume of 9,533,857 shares, compared to its average volume of 8,786,401. The company has a market capitalization of $112,920.00, a price-to-earnings ratio of 29.23, a P/E/G ratio of 1.98 and a beta of 1.08. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.46 and a current ratio of 1.59. Bristol-Myers Squibb Co has a one year low of $51.56 and a one year high of $69.39.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Monday, February 5th. The biopharmaceutical company reported $0.68 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.67 by $0.01. The business had revenue of $5.45 billion for the quarter, compared to the consensus estimate of $5.35 billion. Bristol-Myers Squibb had a return on equity of 33.68% and a net margin of 4.85%. The firm’s quarterly revenue was up 3.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.63 earnings per share. research analysts predict that Bristol-Myers Squibb Co will post 3.22 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Thursday, February 1st. Shareholders of record on Friday, January 5th were issued a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a dividend yield of 2.32%. The ex-dividend date was Thursday, January 4th. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently 67.80%.

In other news, EVP Sandra Leung sold 156,582 shares of the stock in a transaction on Monday, December 4th. The stock was sold at an average price of $63.37, for a total value of $9,922,601.34. Following the completion of the transaction, the executive vice president now directly owns 584,373 shares in the company, valued at approximately $37,031,717.01. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Thomas J. Jr. Lynch sold 5,300 shares of the stock in a transaction on Tuesday, December 12th. The shares were sold at an average price of $63.24, for a total value of $335,172.00. Following the completion of the transaction, the executive vice president now owns 9,251 shares of the company’s stock, valued at $585,033.24. The disclosure for this sale can be found here. Company insiders own 0.23% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This story was first published by Week Herald and is owned by of Week Herald. If you are reading this story on another site, it was illegally copied and reposted in violation of U.S. & international copyright law. The correct version of this story can be read at https://weekherald.com/2018/02/15/tt-international-sells-11953-shares-of-bristol-myers-squibb-co-bmy.html.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply